Thyrotoxicosis with pegylated interferon alfa-2b.
Lowndes SA. et al, (2010), Arch Dermatol, 146, 1273 - 1275
A phase 2 study of vatalanib in metastatic melanoma patients.
Cook N. et al, (2010), Eur J Cancer, 46, 2671 - 2673
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
Sabharwal A. et al, (2010), Cancer Chemother Pharmacol, 66, 829 - 835
Quinone oxidoreductase-2-mediated prodrug cancer therapy.
Middleton MR. et al, (2010), Sci Transl Med, 2
A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.
Molife LR. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OX14503 in patients with advanced solid tumors.
Zweifel M. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
Macaulay VM. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Selective inhibition of proliferating endothelial cells: A phase I study of the novel organoarsenical compound GSAO in patients with advanced solid tumors
Kumaran G. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.
Helfrich I. et al, (2010), J Exp Med, 207, 491 - 503
A reply to evidence-based radiation oncology: oesophagus.
Gillies RS. et al, (2010), Radiother Oncol, 94, 387 - 388
The vascular phenotype, vessel stabilization and maturation affect the resistance to anti-angiogenic therapy in malignant melanoma
Helfrich I. et al, (2010), EUROPEAN JOURNAL OF CELL BIOLOGY, 89, 44 - 44
Resistance to anti-angiogenic therapy is directed by vascular phenotype, vessel stabilization and maturation in malignant melanoma
Helfrich I. et al, (2010), EXPERIMENTAL DERMATOLOGY, 19, 213 - 213
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.
Watson AJ. et al, (2010), Clin Cancer Res, 16, 743 - 749
Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer
Gillies RS. et al, (2010), European Radiology, 1 - 7
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.
Garbe C. et al, (2010), Eur J Cancer, 46, 270 - 283
Erratum: AAA phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer (British Journal of Cancer (2008) 98: (1614-1618) DOI: 10.1038/sj.bjc.6604366))
Khan OA. et al, (2009), British Journal of Cancer, 101
Societal preference values for advanced melanoma health states in the United Kingdom and Australia.
Beusterien KM. et al, (2009), Br J Cancer, 101, 387 - 389
Chemotherapy-based treatment of metastatic melanoma
Atkins MB. et al, (2009), Cutaneous Melanoma, Fifth Edition
A phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer.
Brady J. et al, (2009), J Clin Oncol, 27